Dr. Sumanta K. Pal, MD

Dr. Pal practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Pal's NPI, 1700938180, was assigned on January 17, 2007. Dr. Pal graduated from David Geffen School of Medicine at UCLA in 2003. Dr. Pal holds California license A91718.

Dr. Pal's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Pal's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Pal to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pal practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Pal's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Pal is board certified in medical oncology by the American Board of Internal Medicine. Dr. Pal is licensed in California.

Dmand AI lists lung cancer, lymphoma and prostate cancer among the conditions Dr. Pal treats.

CMS data shows 1,092 Medicare services from Dr. Pal across 5 procedure codes in 2024, for 252 Medicare patients. Medicare paid $88,182 for them.

CMS counts 252 Medicare patients who saw Dr. Pal in 2024. The largest group is 65 to 74, with 133 patients. 75% of them have cancer, and 75% have high blood pressure. 18% are also on Medicaid. Their average risk score is 2.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pal's median patient age at 71, with 25% women.

In 2024, Dr. Pal wrote 582 Medicare Part D claims for 93 patients. 48% of them were for generic drugs. CMS names the drug for 453 of them, across 16 drugs with 11 or more claims each, at $5,693,530 in total drug cost. In 2023, CMS named 368 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Pal for performance year 2024, reported as part of a group. Dr. Pal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Pal as offering telehealth.

Dmand AI links 461 papers to Dr. Pal, published from 2008 to 2025. 2020 was the busiest year, with 37. The most frequent topics are Carcinoma, Renal Cell, Kidney Neoplasms and Antineoplastic Agents. Dr. Pal has published most often in Eur Urol. Dr. Pal's most frequent co-authors are Toni K. Choueiri, MD, Nazli Dizman, MD and Tanya B. Dorff, MD.

Dmand AI links Dr. Pal to 22 clinical trials, 8 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Kidney Neoplasms and Urinary Bladder Neoplasms. City of Hope Medical Center sponsors the most, 8.

CMS Open Payments shows 245 general payments to Dr. Pal from 28 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 37% of the total. Genentech, Inc. paid the most, $79,879. It also lists 23 research payments totaling $23,774 from 2016 to 2024.

Dmand AI lists 7 awards for Dr. Pal, most recently Young Investigator Award in 2013.

Dr. Pal graduated from David Geffen School of Medicine at UCLA in 2003.

Dr. Pal is in network with 14 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.